SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma.

ABSTRACT:

Background

SMAD1, a central mediator in TGF-β signaling, is involved in a broad range of biological activities including cell growth, apoptosis, development and immune response, and is implicated in diverse type of malignancies. Whether SMAD1 plays an important role in multiple myeloma (MM) pathogenesis and can serve as a therapeutic target are largely unknown.

Methods

Myeloma cell lines and primary MM samples were used. Cell culture, cytotoxicity and apoptosis assay, siRNA transfection, Western blot, RT-PCR, Soft-agar colony formation, and migration assay, Chromatin immunoprecipitation (Chip), animal xenograft model studies and statistical analysis were applied in this study.

Results

We demonstrate that SMAD1 is highly expressed in myeloma cells of MM patients with a

SUBMITTER: Wu J 

PROVIDER: S-EPMC8207655 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature